TYK2 and systemic lupus erythematosus: The TYK2 inhibitor, deucravacitinib, was effective in reducing SLE activity and tender and swollen joint counts in patients in an international, randomized, double-blind, placebo-controlled phase II clinical trial [95] and warrants further phase III research trials.